ESMO® 2026 Highlights: Presenter Vignettes – Antonio Giordano

Dr. Antonio Giordano

Antonio Giordano

MD, PhD

Dana-Farber Cancer Institute

1842O

Efficacy and safety of atirmociclib (ATI) + fulvestrant (FUL) in patients (pts) with HR+/HER2– advanced/metastatic breast cancer (mBC) who progressed on prior CDK4/6 inhibitor (CDK4/6i) in a randomized phase 2 study (FOURLIGHT-1)